Trading Day Triumph: Akero Therapeutics Inc (AKRO) Ends at 21.02, a -4.54 Surge/Plunge

Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.

Akero Therapeutics Inc (NASDAQ: AKRO) closed the day trading at $21.02 down -4.54% from the previous closing price of $22.02. In other words, the price has decreased by -$4.54 from its previous closing price. On the day, 0.58 million shares were traded. AKRO stock price reached its highest trading level at $21.91 during the session, while it also had its lowest trading level at $20.58.


For a better understanding of AKRO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 29.27 and its Current Ratio is at 29.27. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.

On September 19, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $69.

On August 28, 2023, UBS started tracking the stock assigning a Buy rating and target price of $83.UBS initiated its Buy rating on August 28, 2023, with a $83 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 01 ’24 when Young Jonathan sold 5,000 shares for $20.15 per share. The transaction valued at 100,750 led to the insider holds 258,306 shares of the business.

Young Jonathan sold 5,000 shares of AKRO for $121,913 on Apr 01 ’24. The Chief Operating Officer now owns 263,306 shares after completing the transaction at $24.38 per share. On Mar 13 ’24, another insider, Cheng Andrew, who serves as the President and CEO of the company, sold 1,969 shares for $28.33 each. As a result, the insider received 55,782 and left with 589,447 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 1453554048 and an Enterprise Value of 715704576.

Stock Price History:

The Beta on a monthly basis for AKRO is -0.28, which has changed by -0.5390413 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, AKRO has reached a high of $58.38, while it has fallen to a 52-week low of $11.25. The 50-Day Moving Average of the stock is -13.19%, while the 200-Day Moving Average is calculated to be -24.85%.

Shares Statistics:

Over the past 3-months, AKRO traded about 1.32M shares per day on average, while over the past 10 days, AKRO traded about 684740 shares per day. A total of 69.15M shares are outstanding, with a floating share count of 57.80M. Insiders hold about 16.42% of the company’s shares, while institutions hold 82.81% stake in the company. Shares short for AKRO as of 1713139200 were 8183677 with a Short Ratio of 6.18, compared to 1710460800 on 9470544. Therefore, it implies a Short% of Shares Outstanding of 8183677 and a Short% of Float of 12.189999.

Earnings Estimates

A comprehensive evaluation of Akero Therapeutics Inc (AKRO) is underway, with the input of 7.0 analysts contributing to its current rating.On average, analysts expect EPS of -$0.95 for the current quarter, with a high estimate of -$0.64 and a low estimate of -$1.15, while EPS last year was -$0.55. The consensus estimate for the next quarter is -$0.97, with high estimates of -$0.78 and low estimates of -$1.2.

Analysts are recommending an EPS of between -$2.89 and -$5.1 for the fiscal current year, implying an average EPS of -$3.89. EPS for the following year is -$4.32, with 8.0 analysts recommending between -$3.36 and -$5.4.

Most Popular

[the_ad id="945"]